Research Network for Hereditary Spastic Paraplegia and Primary Lateral Sclerosis

This is an observational study, meaning it involves collecting information without testing a specific treatment. It's called the Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN). The goal is to better understand hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS), which are conditions causing muscle weakness and stiffness. Researchers will create a shared database, a collection of biological samples (biobank), and a genetic data storage. They also aim to improve collaboration between research centers to standardize how information is collected and prepare for future clinical trials. This study plans to enroll 100 people who have a confirmed diagnosis of hereditary spastic paraplegia type 4 (SPG4) or type 5A (SPG5A). The success of this study will be measured by establishing these resources and collaborations within two years.

Study design
This is an observational study that aims to enroll 100 participants. It is not testing a specific intervention but rather collecting data to understand conditions better.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goals of this study are measured at 2 years, focusing on establishing research infrastructure and collaborations.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06553976

Spastic Paraplegia - Centers of Excellence Research Network

Recruiting
Not specifiedAll AgesObservational
Boston Children's Hospital
~100 participants
Updated 2026-03-18 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Establish a shared clinical database, biobank of biospecimen samples, and a central repository for the storage of all genetic data in SP-CERN.
Measured over 2 years
+3 more outcomes measured
Hereditary Spastic Paraplegia
Primary Lateral Sclerosis
SPG4
SPG5A
Spastic Paraplegia 4
Spastic Paraplegia 5A
Early Onset Hereditary Spastic Paraplegia
Neuromuscular Diseases
Spastic Paraplegia, Hereditary

NCT06553976

Where you'd take part

This study runs at 11 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Boston Children's Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohiostudy coordinator listed

    Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusettsstudy coordinator listed

    Not yet recruiting

  • Scottish Rite for Children

    Dallas, Texasstudy coordinator listed

    Not yet recruiting

  • Seattle Children's Hospital

    Seattle, Washingtonstudy coordinator listed

    Not yet recruiting

  • Texas Children's Hospital

    Houston, Texasstudy coordinator listed

    Not yet recruiting

  • University of Iowa Carver College of Medicine

    Iowa City, Iowastudy coordinator listed

    Not yet recruiting

  • University of Miami Miller School of Medicine

    Miami, Floridastudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female patients of all ages with a clinical and molecular diagnosis of hereditary spastic paraplegia type 4 (SPG4, SPAST) or hereditary spastic paraplegia type 5A (SPG5A, CYP7B1).

Exclusion

Not having such a diagnosis and/or not being related to such individual.
  • Establish a shared clinical database, biobank of biospecimen samples, and a central repository for the storage of all genetic data in SP-CERN.2 years
  • Synchronize collaborations between institutions and clinical sites through a central research protocol to standardize outcome measures and maximize the quality of research and data to ensure clinical trial readiness by regulatory standards.2 years
  • Test key elements in pilot projects2 years
  • Build comprehensive programs for advancements in diagnosis, provide more opportunities for innovative treatments, and increase access to high-quality healthcare for HSP and PLS patients.2 years